Zai Lab Limited ADR Dossier
Qualitative Analysis
Business overview
Zai Lab Ltd (NASDAQ: ZLAB; HKEX: 9688) is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that address high unmet medical needs in oncology, immunology, neuroscience, and infectious diseases. Headquartered in Pudong, Shanghai, China, the company has pioneered a highly successful in-licensing model, partnering with global biopharmaceutical innovators to develop and commercialize late-stage drug candidates in Greater China. Its commercial portfolio includes key products such as Zejula (niraparib) for ovarian cancer, VYVGART (efgartigimod alfa) for generalized myasthenia gravis, NUZYRA (omadacycline) for bacterial infections, and Optune (Tumor Treating Fields).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Leveraging a commercially profitable and scaling China business platform to fund and accelerate a global innovation pipeline.
Expected impact: Aims to achieve self-sustained global innovation and bring the first US product approval by 2028.
Advancing zocilurtatug pelitecan (zoci, DLL3 ADC) into pivotal development and global registrational trials.
Expected impact: Positions zoci as Zai Lab's first global oncology launch with potential backbone therapy status.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
To evaluate zocilurtatug pelitecan (zoci) in combination with Amgen's IMDELLTRA (tarlatamab-dlle) for extensive-stage small cell lung cancer (ES-SCLC).
Terms: Not disclosed
To evaluate zocilurtatug pelitecan (zoci) in combination with obrixtamig for small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Terms: Not disclosed
To utilize MediLink's TMALIN antibody-drug conjugate (ADC) platform for the development of ZL-6201 (LRRC15 ADC).
Terms: Zai Lab acquired exclusive worldwide development and commercialization rights.